Apellis Pharmaceuticals (APLS) PT Raised to $35.00 at JPMorgan Chase & Co.

Apellis Pharmaceuticals (NASDAQ:APLS) had its price target hoisted by research analysts at JPMorgan Chase & Co. from $31.00 to $35.00 in a report issued on Friday. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s price target suggests a potential upside of 42.86% from the stock’s current price.

A number of other research analysts have also recently commented on APLS. B. Riley began coverage on Apellis Pharmaceuticals in a research note on Thursday, February 8th. They issued a “buy” rating and a $27.00 target price on the stock. Evercore ISI began coverage on Apellis Pharmaceuticals in a research note on Monday, December 4th. They issued an “outperform” rating on the stock. Finally, Citigroup began coverage on Apellis Pharmaceuticals in a research note on Monday, December 4th. They issued a “buy” rating and a $23.00 target price on the stock.

How to Become a New Pot Stock Millionaire

Apellis Pharmaceuticals (NASDAQ APLS) opened at $24.50 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 27.79 and a quick ratio of 2.75. Apellis Pharmaceuticals has a 12 month low of $12.45 and a 12 month high of $27.53.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sectoral Asset Management Inc bought a new position in Apellis Pharmaceuticals in the fourth quarter valued at $38,033,000. Vivo Capital LLC bought a new position in Apellis Pharmaceuticals in the fourth quarter valued at $31,635,000. BlackRock Inc. bought a new position in Apellis Pharmaceuticals in the fourth quarter valued at $21,096,000. Jennison Associates LLC bought a new position in Apellis Pharmaceuticals in the fourth quarter valued at $13,170,000. Finally, NF Trinity Capital Hong Kong Ltd bought a new position in Apellis Pharmaceuticals in the fourth quarter valued at $7,750,000. 31.29% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3298375/apellis-pharmaceuticals-apls-pt-raised-to-35-00-at-jpmorgan-chase-co.html.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Jewett-Cameron Trading Co  Stake Held by Fort Nelson Partners, LP
Jewett-Cameron Trading Co Stake Held by Fort Nelson Partners, LP
Greenhill & Co.  and GAMCO Investors  Critical Review
Greenhill & Co. and GAMCO Investors Critical Review
STRAKS Tops 1-Day Volume of $24,012.00
STRAKS Tops 1-Day Volume of $24,012.00
KlondikeCoin  Achieves Market Capitalization of $0.00
KlondikeCoin Achieves Market Capitalization of $0.00
Roku  and Its Competitors Head to Head Survey
Roku and Its Competitors Head to Head Survey
Pentair  vs. Metso  Financial Analysis
Pentair vs. Metso Financial Analysis


© 2006-2018 Ticker Report. Google+.